Amundi’s Nektar Therapeutics NKTR Stock Holding History

Amundi’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,795	Closed	-$30.5K	–	2103
2023 Q1	$30.5K	Buy	2,795 +1,705	+156%	+$51.6K	﹤0.01%	1934
2022 Q4	$37.9K	Hold	1,090	–	–	﹤0.01%	1735
2022 Q3	$55K	Buy	+1,090	New	+$64.8K	﹤0.01%	1652

Other funds holding NKTR

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Amundi's NKTR Position: Q2 2023 in Review

Amundi sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 2,795 shares — an estimated $30.5K sold.

Amundi first reported a position in NKTR in Q3 2022 and held it in 3 quarters. The position peaked at $55K in Q3 2022. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.

Amundi reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
Amundi sold 2,795 Nektar Therapeutics shares in Q2 2023, an estimated $30.5K.
Amundi first reported a position in Nektar Therapeutics in Q3 2022 and held it in 3 quarters.
Amundi's Nektar Therapeutics position peaked at $55K in Q3 2022.
146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.

Based on Amundi's 13F filing for Q2 2023, filed 14 Aug 2023.